Telix Pharmaceuticals (TLPPF) Invested Capital (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Invested Capital for 4 consecutive years, with $1.0 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Invested Capital changed N/A year-over-year to $1.0 billion in Q2 2026; TTM through Jun 2026 was $1.0 billion, a N/A change from a year earlier, with the FY2025 full-year figure at $820.4 million, up 10.14% from the prior year.
• Invested Capital was $1.0 billion for Q2 2026 at Telix Pharmaceuticals, up from $820.4 million in the prior quarter.
• Over five years, Invested Capital peaked at $1.0 billion in Q2 2026 and troughed at $102.9 million in Q4 2023.
• A 4-year average of $668.1 million and a median of $782.6 million in 2025 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital jumped 623.8% in 2024 and increased 10.14% in 2025, its largest moves.
• Over 4 years, Invested Capital stood at $102.9 million in 2023, then jumped by 623.8% to $744.9 million in 2024, then rose by 10.14% to $820.4 million in 2025, then gained by 22.39% to $1.0 billion in 2026.
• The last three Invested Capital figures came in at $1.0 billion (Q2 2026), $820.4 million (Q4 2025), and $744.9 million (Q4 2024), per Business Quant data.